Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Michaud, Henri Alexandre ^a   de Mulder, Miguel ^a   SenGupta, Devi ^a   Deeks, Steven G ^a   Martin, Jeffrey N ^a   Pilcher, Christopher D ^a   Hecht, Frederick M ^a   Sacha, Jonah B ^b,c   Nixon, Douglas F ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Alternative transcripts; Antibody; Elite controllers; Endogenous retroviruses; Envelope; HERV; HIV; Transmembrane

Indexed keywords

EPITOPE; MESSENGER RNA; PROTEIN HML2; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; ENDOGENOUS RETROVIRUS; EPITOPE MAPPING; FEMALE; GENE EXPRESSION REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HML GENE; HUMAN; HUMAN CELL; HUMAN ENDOGENOUS RETROVIRUS K; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; TRANSACTIVATION; TRANSCRIPTION REGULATION; VIRUS GENE; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; ENDOGENOUS RETROVIRUSES; FEMALE; GENE EXPRESSION; HIV INFECTIONS; HUMANS; MALE; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRAL ENVELOPE PROTEINS; VIRUS ACTIVATION;

EID: 84893416710     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-11-10     Document Type: Article

References (59)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921. 10.1038/35057062, 11237011.
2. Lee YN, Bieniasz PD. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 2007, 3:e10. 10.1371/journal.ppat.0030010, 1781480, 17257061.
3. Goff SP. Retrovirus restriction factors. Mol Cell 2004, 16:849-859. 10.1016/j.molcel.2004.12.001, 15610729.
4. Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 2011, 8:90. 10.1186/1742-4690-8-90, 3228705, 22067224.
5. Kurth R, Bannert N. Beneficial and detrimental effects of human endogenous retroviruses. Int J Cancer 2010, 126:306-314. 10.1002/ijc.24902, 19795446.
6. Jha AR, Nixon DF, Rosenberg MG, Martin JN, Deeks SG, Hudson RR, Garrison KE, Pillai SK. Human endogenous retrovirus K106 (HERV-K106) was infectious after the emergence of anatomically modern humans. PLoS One 2011, 6:e20234. 10.1371/journal.pone.0020234, 3102101, 21633511.
7. Lower R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, Kurth R. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci USA 1993, 90:4480-4484. 10.1073/pnas.90.10.4480, 46535, 8506289.
8. Ehlhardt S, Seifert M, Schneider J, Ojak A, Zang KD, Mehraein Y. Human endogenous retrovirus HERV-K(HML-2) Rec expression and transcriptional activities in normal and rheumatoid arthritis synovia. J Rheumatol 2006, 33:16-23.
9. Herve CA, Lugli EB, Brand A, Griffiths DJ, Venables PJ. Autoantibodies to human endogenous retrovirus-K are frequently detected in health and disease and react with multiple epitopes. Clin Exp Immunol 2002, 128:75-82. 10.1046/j.1365-2249.2002.01735.x, 1906363, 11982593.
10. Lai OY, Chen H, Michaud HA, Hayashi G, Kuebler PJ, Hultman GK, Ariza ME, Williams MV, Batista MD, Nixon DF, et al. Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility. J Invest Dermatol 2012, 132:1833-1840. 10.1038/jid.2012.69, 3375357, 22437317.
11. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557. 3235490, 21051598.
12. Sicat J, Sutkowski N, Huber BT. Expression of human endogenous retrovirus HERV-K18 superantigen is elevated in juvenile rheumatoid arthritis. J Rheumatol 2005, 32:1821-1831.
13. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol 2008, 82:8743-8761. 10.1128/JVI.00584-08, 2519685, 18562517.
14. Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005, 65:4172-4180. 10.1158/0008-5472.CAN-04-2983, 15899808.
15. Goering W, Ribarska T, Schulz WA. Selective changes of retroelement expression in human prostate cancer. Carcinogenesis 2011, 32:1484-1492. 10.1093/carcin/bgr181, 21828060.
16. Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, et al. Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun 2008, 8:15. 2935773, 19006261.
17. Katoh I, Mirova A, Kurata S, Murakami Y, Horikawa K, Nakakuki N, Sakai T, Hashimoto K, Maruyama A, Yonaga T, et al. Activation of the long terminal repeat of human endogenous retrovirus K by melanoma-specific transcription factor MITF-M. Neoplasia 2011, 13:1081-1092. 3223611, 22131883.
18. Schanab O, Humer J, Gleiss A, Mikula M, Sturlan S, Grunt S, Okamoto I, Muster T, Pehamberger H, Waltenberger A. Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma. Pigment Cell Melanoma Res 2011, 24:656-665. 10.1111/j.1755-148X.2011.00860.x, 21501418.
19. Wang-Johanning F, Frost AR, Jian B, Azerou R, Lu DW, Chen DT, Johanning GL. Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. Cancer 2003, 98:187-197. 10.1002/cncr.11451, 12833471.
20. Boller K, Janssen O, Schuldes H, Tonjes RR, Kurth R. Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. J Virol 1997, 71:4581-4588. 191680, 9151852.
21. Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, Lower J, Lower R. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses 2008, 24:717-723. 10.1089/aid.2007.0286, 18462078.
22. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, Sheehy EM, , Ortiz GM, Ogg SG, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses 2006, 22:52-56. 10.1089/aid.2006.22.52, 16438646.
23. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 2002, 62:5510-5516.
24. Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, Sastry KJ, Piyathilake CJ, Hunt KK, Johanning GL. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res 2008, 68:5869-5877. 10.1158/0008-5472.CAN-07-6838, 18632641.
25. Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, et al. Expression of human endogenous retrovirus type K envelope protein Is a novel candidate prognostic marker for human breast cancer. Genes Cancer 2011, 2:914-922. 10.1177/1947601911431841, 3352153, 22593804.
26. Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM, Erickson AL, Agrawal A, Spotts G, Hecht FM, et al. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog 2007, 3:e165. 10.1371/journal.ppat.0030165, 2065876, 17997601.
27. Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, Hunter DV, Martin E, John VM, Zhan W, Faruk NF, et al. HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest 2012, 122(2):4473-89. 3533554, 23143309.
28. Contreras-Galindo R, Kaplan MH, Contreras-Galindo AC, Gonzalez-Hernandez MJ, Ferlenghi I, Giusti F, Lorenzo E, Gitlin SD, Dosik MH, Yamamura Y, Markovitz DM. Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. J Virol 2012, 86:262-276. 10.1128/JVI.00602-11, 3255917, 22031938.
29. SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE, Loh L, Jones RB, Garrison KE, Martin JN, et al. Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol 2011, 85:6977-6985. 10.1128/JVI.00179-11, 3126607, 21525339.
30. van der Kuyl AC. HIV infection and HERV expression: a review. Retrovirology 2012, 9:6. 10.1186/1742-4690-9-6, 3311604, 22248111.
31. Dewannieux M, Blaise S, Heidmann T. Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses. J Virol 2005, 79:15573-15577. 10.1128/JVI.79.24.15573-15577.2005, 1315997, 16306628.
32. Hanke K, Kramer P, Seeher S, Beimforde N, Kurth R, Bannert N. Reconstitution of the ancestral glycoprotein of human endogenous retrovirus k and modulation of its functional activity by truncation of the cytoplasmic domain. J Virol 2009, 83:12790-12800. 10.1128/JVI.01368-09, 2786854, 19812154.
33. Kammerer U, Germeyer A, Stengel S, Kapp M, Denner J. Human endogenous retrovirus K (HERV-K) is expressed in villous and extravillous cytotrophoblast cells of the human placenta. J Reprod Immunol 2011, 91:1-8.
34. Laderoute MP, Giulivi A, Larocque L, Bellfoy D, Hou Y, Wu HX, Fowke K, Wu J, Diaz-Mitoma F. The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia. Aids 2007, 21:2417-2424. 10.1097/QAD.0b013e3282f14d64, 18025878.
35. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 1996, 93:5177-5184. 10.1073/pnas.93.11.5177, 39218, 8643549.
36. Goedert JJ, Sauter ME, Jacobson LP, Vessella RL, Hilgartner MW, Leitman SF, Fraser MC, Mueller-Lantzsch NG. High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. Cancer Epidemiol Biomarkers Prev 1999, 8:293-296.
37. Vogetseder W, Dumfahrt A, Mayersbach P, Schonitzer D, Dierich MP. Antibodies in human sera recognizing a recombinant outer membrane protein encoded by the envelope gene of the human endogenous retrovirus K. AIDS Res Hum Retroviruses 1993, 9:687-694. 10.1089/aid.1993.9.687, 8396402.
38. Imbeault M, Giguere K, Ouellet M, Tremblay MJ. Exon level transcriptomic profiling of HIV-1-infected CD4(+) T cells reveals virus-induced genes and host environment favorable for viral replication. PLoS Pathog 2012, 8:e1002861. 10.1371/journal.ppat.1002861, 3410884, 22876188.
39. Moiani A, Mavilio F. Alternative splicing caused by lentiviral integration in the human genome. Methods in enzymology 2012, 507:155-169.
40. Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, Cocchiarella F, Lidonnici MR, Ferrari G, Mavilio F. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012, 122:1653-1666. 10.1172/JCI61852, 3347495, 22523069.
41. Chang ST, Sova P, Peng X, Weiss J, Law GL, Palermo RE, Katze MG. Next-generation sequencing reveals HIV-1-mediated suppression of T cell activation and RNA processing and regulation of noncoding RNA expression in a CD4+ T cell line. mBio 2011, 2:e00134-11. 3175625, 21933919.
42. Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. Frontiers in oncology 2013, 3:246. 3778440, 24066280.
43. Boller K, Schonfeld K, Lischer S, Fischer N, Hoffmann A, Kurth R, Tonjes RR. Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J Gen Virol 2008, 89:567-572. 10.1099/vir.0.83534-0, 18198388.
44. Haraguchi S, Good RA, Cianciolo GJ, Engelman RW, Day NK. Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. J Leukoc Biol 1997, 61:654-666.
45. Kraus B, Fischer K, Buchner SM, Wels WS, Lower R, Sliva K, Schnierle BS. Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. PLoS One 2013, 8:e72756. 10.1371/journal.pone.0072756, 3758348, 24023643.
46. Mangeney M, Heidmann T. Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc Natl Acad Sci USA 1998, 95:14920-14925. 10.1073/pnas.95.25.14920, 24551, 9843991.
47. Oostendorp RA, Schaaper WM, Post J, Meloen RH, Scheper RJ. Synthetic hexapeptides derived from the transmembrane envelope proteins of retroviruses suppress N-formylpeptide-induced monocyte polarization. J Leukoc Biol 1992, 51:282-288.
48. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012, 104:189-210. 10.1093/jnci/djr540, 3274512, 22247020.
49. Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, et al. Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett 2007, 252:290-298. 10.1016/j.canlet.2007.01.003, 17320278.
50. Sacha JB, Kim IJ, Chen L, Ullah JH, Goodwin DA, Simmons HA, Schenkman DI, von Pelchrzim F, Gifford RJ, Nimityongskul FA, et al. Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements Is safe and immunogenic. J Immunol 2012, 189:1467-1479. 10.4049/jimmunol.1200079, 3401319, 22745376.
51. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871. 10.1126/science.6189183, 6189183.
52. Wain-Hobson S, Vartanian JP, Henry M, Chenciner N, Cheynier R, Delassus S, Martins LP, Sala M, Nugeyre MT, Guetard D, et al. LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science 1991, 252:961-965. 10.1126/science.2035026, 2035026.
53. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 2009, 83:8289-8292. 10.1128/JVI.00709-09, 2715758, 19474095.
54. Takeuchi Y, McClure MO, Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 2008, 82:12585-12588. 10.1128/JVI.01726-08, 2593302, 18842727.
55. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905. 10.1128/AAC.46.6.1896-1905.2002, 127242, 12019106.
56. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864. 109730, 9525605.
57. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology 2002, 3:RESEARCH0034. 126239, 12184808.
58. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348. 10.1016/0092-8674(86)90590-8, 3094962.
59. Franz B, May KF, Dranoff G, Wucherpfennig K. Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood 2011, 118:348-357. 10.1182/blood-2011-03-341917, 3138687, 21551230.